.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02B_HormoneAntagonistsAndRelatedAgents.L02BA01_Tamoxifen.Tamoxifen .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02B_HormoneAntagonistsAndRelatedAgents.L02BA01_Tamoxifen.Tamoxifen| name: | Tamoxifen | |
| ATC code: | L02BA01 | route: | oral |
| compartments: | 2 | |
| dosage: | 20 | mg |
| volume of distribution: | 62 | L |
| clearance: | 1.04 | L/h/kg |
| other parameters in model implementation | ||
Tamoxifen is a selective estrogen receptor modulator (SERM) widely used in the treatment and prevention of breast cancer, particularly hormone receptor-positive breast cancer. It remains a standard of care for pre-menopausal and post-menopausal women and is approved and in clinical use worldwide.
Pharmacokinetic parameters in healthy female volunteers, assessed after a single oral dose.
Koubek, EJ, et al., & Reid, JM (2022). Population Pharmacokinetics of Z-Endoxifen in Patients With Advanced Solid Tumors. Journal of clinical pharmacology 62(9) 1121–1131. DOI:10.1002/jcph.2053 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35358345
Ducharme, J, et al., & Wainer, IW (1997). Tamoxifen metabolic patterns within a glioma patient population treated with high-dose tamoxifen. British journal of clinical pharmacology 43(2) 189–193. DOI:10.1046/j.1365-2125.1997.05029.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/9131952
Skirvin, JA, & Lichtman, SM (2002). Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer. Drugs & aging 19(1) 25–42. DOI:10.2165/00002512-200219010-00003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11929325